DOPE
Based on 14 publication(s) in Google Scholar
DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity : 99.96%
- CAS No.: 4004-05-1
- Formula: C41H78NO8P
- Molecular Weight:744.03
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-113424A
1,2-Dioleoyl-sn-glycero-3-phosphocholine -
HY-W040193
DSPC -
HY-N0322
Cholesterol (from animal) -
HY-112764
mPEG2000-DMG -
HY-112754A
DOTAP chloride -
HY-112251
D-Lin-MC3-DMA -
HY-134541
SM-102 -
HY-141613
1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium -
HY-141571
DOPG sodium -
HY-142979
DSPE-PEG 2000 -
HY-109506
DPPC -
HY-N0171A
Beta-Sitosterol (purity>98%)
Publications Citing Use of MedChemExpress (MCE) DOPE
More- Exp Mol Med. 2026 Jul;58(7):2339-2355.
- J Nanobiotechnology. 2024 Nov 27;22(1):733. [Abstract]
- Cell Rep Med. 2026 Feb 17;7(2):102580. [Abstract]
- Biomaterials. 2026 Jun:329:123927. [Abstract]
- Chem Eng J. 2026 Mar 24.
- Chem Eng J. 2024 Jun 15, 490, 151775.
- Cell Death Dis. 2026 Apr 8;17(1):499. [Abstract]
- Adv Healthc Mater. 2025 Sep 4:e03771. [Abstract]
- ACS Appl Mater Interfaces. 2025 Mar 5;17(9):13646-13659. [Abstract]
- Mol Ther Nucleic Acids. 2026 Jul 14;37(3):103012.
- Microbiol Spectr. 2025 Nov 5;13(12):e0143825. [Abstract]
- Pathol Res Pract. 2025 Sep:273:156138. [Abstract]
- bioRxiv. 2026 May 4.
- SSRN. 2025 May 6.
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
FITC-labeled DOPE (2 h) is internalized by IEC-6 rat intestinal epithelial cells within 2 hours, and fluorescence is detectable in both the cytoplasm and nucleus[1].
DOPE (5 μg/mL; 1 h) restores the migratory capacity of IEC-6 rat intestinal epithelial cells inhibited by LPS[1].
DOPE (5 μg/mL; 1 h) restores the migration and proliferation capacities, as well as the expression of tight junction proteins (ZO-1, occludin), in RSL3-induced ferroptotic rat intestinal epithelial cells IEC-6[1].
DOPE enhances the uptake efficiency of mesenchymal stem cells for AMSC-MP, improves the cell adhesion ability to scaffolds, upregulates the expression of osteogenesis-related gene RUNX2, and enhances in vitro osteogenic differentiation capacity. Moreover, this formulation exhibits excellent biocompatibility and does not exert adverse effects on cell viability[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 4004-05-1
-
Appearance Solid-Liquid Mixture
-
Molecular Weight 744.03
-
Formula C41H78NO8P
-
Color White to light yellow
-
SMILES
O=P(OC[C@H](OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O)(OCCN)O
-
Synonyms
Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
-
J Nanobiotechnology
Sele-targeted siRNA liposome nanoparticles inhibit pathological scars formation via blocking the cross-talk between monocyte and endothelial cells: a preclinical study based on a novel mice scar model. [Abstract]2024 Nov 27;22(1):733. PMID: 39593088 -
Cell Rep Med
Synthetic cleavage-resistant TREM2 boosts macrophage efferocytosis to treat inflammatory diseases. [Abstract]2026 Feb 17;7(2):102580. PMID: 41616764 -
Biomaterials
AI agent-based discovery of D-enantiomeric antimicrobial peptides against multidrug-resistant bacterial infection. [Abstract]2026 Jun:329:123927. PMID: 41443039 -
-
-
Cell Death Dis
OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. [Abstract]2026 Apr 8;17(1):499. PMID: 41951612 -
Adv Healthc Mater
Engineered Immunoagonist Non-Coding RNA (incRNA) Activates Dual TLR Pathways for Cancer Immunotherapy. [Abstract]2025 Sep 4:e03771. PMID: 40906496 -
ACS Appl Mater Interfaces
Self-Assembling Lauroylated Antimicrobial Peptide with Superior Antimicrobial Activity, Stability, and Selectivity. [Abstract]2025 Mar 5;17(9):13646-13659. PMID: 39964258 -
-
Microbiol Spectr
Lipid nanoparticle-delivered mRNA vaccine encoding the MOMP of Chlamydia psittaci elicits protective immune responses in BALB/c mice. [Abstract]2025 Nov 5;13(12):e0143825. PMID: 41190885 -
Pathol Res Pract
Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]2025 Sep:273:156138. PMID: 40694986 -
-
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (67.20 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 10 mg/mL (13.44 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (2.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 2 mg/mL (2.69 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2 mg/mL (2.69 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chen Y, et al. Human breast milk-derived phospholipid DOPE ameliorates intestinal injury associated with NEC by inhibiting ferroptosis. Food Funct. 2024;15(21):10811-10822. Published 2024 Oct 28. [Content Brief]
[4]. Cui GH, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer's disease. Immun Ageing. 2019;16:10. Published 2019 May 13. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.3440 mL | 6.7202 mL | 13.4403 mL | 33.6008 mL |
| 5 mM | 0.2688 mL | 1.3440 mL | 2.6881 mL | 6.7202 mL | |
| 10 mM | 0.1344 mL | 0.6720 mL | 1.3440 mL | 3.3601 mL | |
| DMSO | 15 mM | 0.0896 mL | 0.4480 mL | 0.8960 mL | 2.2401 mL |
| 20 mM | 0.0672 mL | 0.3360 mL | 0.6720 mL | 1.6800 mL | |
| 25 mM | 0.0538 mL | 0.2688 mL | 0.5376 mL | 1.3440 mL | |
| 30 mM | 0.0448 mL | 0.2240 mL | 0.4480 mL | 1.1200 mL | |
| 40 mM | 0.0336 mL | 0.1680 mL | 0.3360 mL | 0.8400 mL | |
| 50 mM | 0.0269 mL | 0.1344 mL | 0.2688 mL | 0.6720 mL | |
| 60 mM | 0.0224 mL | 0.1120 mL | 0.2240 mL | 0.5600 mL |
DOPE Related Classifications
HY-112005 Related Classifications
Powered by Bioz